Bio Spectrum

Will the second COVID-19 wave overwhelm the pharma companies?

- Dr Sandeep Narula,

Associate Professor, Assistant Dean, School of Pharmaceut­ical, IIHMR University, Jaipur

It’s been more than a year that we are surviving under the constant threat of ClsIa-19. The same is the case with business organisati­ons. Business is not at its usual. With first giving respite around November-aecember 2020, and healthcare and pharma business trying to make and cover the grounds, but only for the second wave to reckon back this with more power and brutality. The second wave has created severe havoc on the lives of the people, with deaths per million population in India crossing the 180 mark and bringing the entire healthcare system to collapse.

With experts predicting the third wave of the pandemic, how will the businesses, economy and social life cope up? Are we really prepared for the new social and business ecosystem? Will the government help businesses combat the huge losses? Will the employment issues can be addressed? Especially with respect to the pharma business, how the pharma companies will make their transition­s from the existing business model to the new digital business model. Is the top leadership (barring big MNC pharma giants) really equipped for future digital challenges?

As per BloombergQ­uint opinion survey of 2018, the digital literacy of India was only 1.67 per cent, if I extrapolat­e further by the same growth rate then also by December 2020, it will barely touch 2 per cent. As per Hootsuite January 2021 stats, individual internet users are 20.1 per cent, 32.3 per cent of the population on Social media, with YouTube leading from the front followed by Facebook, WhatsApp and Instagram.

As per Gartner, healthcare, companies are experienci­ng ‘unpreceden­ted levels of disruption’, among the major reasons for disruption mentioned are internal organisati­on changes and cost pressure followed by regulation, compliance. It is estimated by Gartner, that only 20 per cent of the “fit” healthcare organizati­ons are going to thrive and the remaining will be left behind. It is already a proven fact that the companies which are currently operating on digital platforms, their CAGR is 12 -15 per cent higher than the traditiona­l business organizati­ons.

Accepting ‘change’

The biggest challenge with the pharmaceut­ical companies is not of Digital Transforma­tion, but of ‘Transforma­tion’. Today the major challenge pharmaceut­ical companies are facing is from their own domain companies, but from the tech-driven domain companies like Apple, Microsoft, Google, Amazon and many others. As these tech-driven companies already have a readymade ecosystem with strong customer data (Demographi­c and Psychograp­hic) and details that includes Healthcare profession­als (HCPs) and Patients, hence it is very easy for them to offer the desired solutions. The recent rise of companies like Fitbit, GoogleFit, MIFit, Apple Health, Samsung Health apps in the wellness domain is a clear example that pharma is set to lose its share to these tech-driven companies. These tech-driven companies have already made a paradigm shift from “illness” to “Wellness”. The pharmaceut­ical companies to date are focusing on illness and treating a sick person as their customer, but these tech-driven companies don’t talk about any disease but they are focusing on ‘fitness’, ‘staying fit and healthy’ and by this definition, the entire universe is now their customer. Now, this is known as Transforma­tion, where, from a small percentage or a fraction of the population, you start targeting a bigger mass or may universe, then this scale is known as transforma­tion. And when you want to reach/ address this scale, this magnitude of customers, then your traditiona­l business model will not work and for this, then you need a model which allows you to reach lakhs and crores of the customers with ease and convenienc­e and this scale is offered by digital platforms.

No recourse to digitalisa­tion

One thing is certain that for pharmaceut­ical companies, the pre-COVID period, in terms of HCP physical coverage and interactio­n, is not going to come back. The pharma companies have to adopt the digital route to reach HCPs as HCPs are finding digital platform a better option, as Digital is the perfect route for recovery and growth.

As on date, the pharmaceut­ical companies barring few big pharma companies, the socalled digital transforma­tion is beyond their realm. To go for Digital Transforma­tion the companies need to invest heavily on Informatio­n Technology ( IT) , starting cloud computing, as investing in cloud computing will offer them a competitiv­e advantage, as it is this investment only which will offer them suitable platforms to operationa­lise their business strategies. Needless to say, here, in place of the traditiona­l IT manager, companies need to hire a chief informatio­n officer ( CIO) or chief technology officer (CTO). Keeping in view the volumes of data, the digital adoption and applicatio­n offer, pharmaceut­ical companies not only need to hire chief data officer ( CDO) but also they need to change their operating model too keeping the disruption­s occurring frequently at the marketplac­e. Hence, it is certain that minor or fringe changes or changes occurring at the edges, are not going to yield the desired response and it will yield the investment below the cost of capital.

Also, today HCPs, they are not looking for product promotion, but they are looking beyond the products. The HCPs, they are not using one channel of promotion, rather there are multiple channels through which they are getting exposure to their product/ services. So, pharmaceut­ical companies instead of going for Multichann­el marketing, they need to design the concept of Omnichanne­l marketing and this itself is a big challenge for the Indian pharmaceut­ical companies.

Todays’ HCPs they are more used to Omnichanne­l marketing and this experience they are already getting in their daily routine product/ services which is offered by the companies like Amazon and Netflix. Pharmaceut­ical companies need to design and think for their product promotion in this manner or on these lines and they have created an ecosystem through which they can offer their product/ services to HCPs. In other words, they have created an EXPERIENCE in such a manner that the HCP is fully engrossed or immersed in the company brand promotion ecosystem. And to create this ecosystem/ experience, pharmaceut­ical companies need to hire a Chief Experience Officer ( CEO).

Apart from above three challenges, the fourth challenge which the pharmaceut­ical companies will have to face is the emergence of ’ Substituti­on power of pharmacist’. Due to the pandemic, the supply chain of majority of the pharmaceut­ical business organisati­on was/ is interrupte­d due to the shortage of active pharmaceut­ical ingredient­s (APIs) and raw material. During this period, even the HCPs also have given the consent and acceptance of the substituti­on. Today this prescripti­on substituti­on is more than 40 per cent, as this is a paradigm shift in the pharmaceut­ical business selling. Pharmaceut­ical companies have to think about these pharmacist­s also as their customer, and they have to offer ‘ desired’ customer services to these pharmacist as well. Also, these local pharmacist­s have stepped up their services in the local community and are now offering various form of extended services like blood pressure monitoring, blood testing and even Video Calling services to the HCPs apart from free home deliveries of medicines.

In days to comes, if pharmaceut­ical companies need to grow and sustain then they have embrace the above mentioned challenges and have to think of digital adoption first and then transforma­tion which will eventually give them scale and magnitude both.

As on date, the pharmaceut­ical companies barring few big pharma companies, the so-called digital transforma­tion is beyond their realm. To go for Digital Transforma­tion the companies need to invest heavily on IT , starting cloud computing, as investing in cloud computing will offer them a competitiv­e advantage, as it is this investment only which will offer them suitable platforms to operationa­lise their business strategies. Needless to say, here, in place of the traditiona­l IT manager, companies need to hire a CIO or CTO.

 ??  ??
 ??  ?? «
Dr Sandeep Narula, Associate Professor, Assistant Dean, School of Pharmaceut­ical, IIHMR University, Jaipur
« Dr Sandeep Narula, Associate Professor, Assistant Dean, School of Pharmaceut­ical, IIHMR University, Jaipur

Newspapers in English

Newspapers from India